Education
About Us
Working with TipRanks
Follow Us
GeneDx Holdings (WGS)
NASDAQ:WGS
WGS Stock Chart & Stats
$91.44
-$4.29(-4.42%)
At close: 4:00 PM EST
$91.44
-$4.29(-4.42%)
Day’s Range― - ―
52-Week Range$55.17 - $170.87
Previous CloseN/A
Volume338.68K
Average Volume (3M)688.57K
Market Cap
$2.62B
Enterprise Value$2.62B
Total Cash (Recent Filing)$155.08M
Total Debt (Recent Filing)$113.16M
Price to Earnings (P/E)1503.6
Beta1.31
Next Earnings
Feb 23, 2026EPS Estimate
0.1Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.49
Shares Outstanding28,904,590
10 Day Avg. Volume811,605
30 Day Avg. Volume688,567
Financial Highlights & Ratios
PEG Ratio0.54
Price to Book (P/B)8.43
Price to Sales (P/S)6.77
P/FCF Ratio-60.81
Enterprise Value/Market Cap1.00
Enterprise Value/Revenue6.52
Enterprise Value/Gross Profit9.36
Enterprise Value/Ebitda82.43
Forecast
1Y Price Target
$171.67Price Target Upside87.74% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Earnings And Analyst RatingAnalyst's recommendation remains BUY after preliminary quarterly results modestly exceeded estimates and full-year guidance came in above consensus, supporting upside to the shares.
Market Adoption And Product LaunchBroader adoption by general pediatricians following guideline updates, improving insurance denial trends, and the planned launch of a prenatal genome test create multiple avenues for sustained revenue growth.
Testing Volume GrowthStrong growth in whole exome and whole genome testing volume, together with higher average selling prices, can expand revenue and improve margins.
Bears Say
Cash Flow And Funding RiskSustained investment spending may increase cash burn and raise the likelihood of additional funding needs, which could dilute shareholders or increase leverage.
Profitability Risk From Investment SpendingElevated expenses from investments to seed long-term growth could pressure adjusted net income and investor sentiment, creating near-term profitability risk.
Valuation And Sentiment VolatilityPersistent cost increases and uncertainty around the timing of returns on growth investments could amplify share-price volatility as investors reassess valuation assumptions.
GeneDx Holdings News
WGS FAQ
What was GeneDx Holdings’s price range in the past 12 months?
GeneDx Holdings lowest stock price was $55.17 and its highest was $170.87 in the past 12 months.
What is GeneDx Holdings’s market cap?
GeneDx Holdings’s market cap is $2.62B.
When is GeneDx Holdings’s upcoming earnings report date?
GeneDx Holdings’s upcoming earnings report date is Feb 23, 2026 which is in 8 days.
How were GeneDx Holdings’s earnings last quarter?
GeneDx Holdings released its earnings results on Oct 28, 2025. The company reported $0.49 earnings per share for the quarter, beating the consensus estimate of $0.423 by $0.067.
Is GeneDx Holdings overvalued?
According to Wall Street analysts GeneDx Holdings’s price is currently Undervalued.
Does GeneDx Holdings pay dividends?
GeneDx Holdings does not currently pay dividends.
What is GeneDx Holdings’s EPS estimate?
GeneDx Holdings’s EPS estimate is 0.1.
How many shares outstanding does GeneDx Holdings have?
GeneDx Holdings has 28,904,590 shares outstanding.
What happened to GeneDx Holdings’s price movement after its last earnings report?
GeneDx Holdings reported an EPS of $0.49 in its last earnings report, beating expectations of $0.423. Following the earnings report the stock price went up 5.212%.
Which hedge fund is a major shareholder of GeneDx Holdings?
Currently, no hedge funds are holding shares in WGS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
GeneDx Holdings Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$171.67 (87.74% Upside)
$171.67 (87.74% Upside)
Blogger Sentiment
Bullish
WGS Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 183.0K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $6.1M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days ▲ 2.0%
Last 30 Days ▼ 3.5%
Last 30 Days ▼ 3.5%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
34.86%
12-Months-Change
Fundamentals
Return on Equity
0.84%
Trailing 12-Months
Asset Growth
20.81%
Trailing 12-Months
Company Description
GeneDx Holdings
GeneDx Holdings Corp. is a patient centered health intelligence company. It engages in transforming healthcare by applying AI and machine learning to multidimensional, longitudinal clinical and genomic data to build dynamic models of human health and defining optimal, individualized health trajectories. The firm, through its Centrellis health intelligence platform, generates a more complete understanding of disease and wellness and provides science-driven solutions to the most pressing medical needs. The company was founded by Eric Schadt in October 2015 and is headquartered in Stamford, CT.
WGS Company Deck
WGS Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call presented a strong performance with significant revenue growth and improved margins. The FDA breakthrough designation adds further validation to GeneDx's technology. However, potential ASP declines and market underpenetration in NICUs were noted challenges. Overall, the highlights outweigh the lowlights, indicating a positive outlook.View all WGS earnings summariesWGS Revenue Breakdown
96.59% Diagnostic test revenue
3.41% Other
WGS Stock 12 Month Forecast
Average Price Target
$171.67
▲(87.74% Upside)
Technical Analysis
Evolent Health
―
10x Genomics
―
Certara
―
SOPHiA GENETICS
―
BrightSpring Health Services, Inc.
―
Ownership Overview
Currently, No data available
---